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a b s t r a c t
22The main physiological function of the lymphatic vasculature is to maintain tissue fluid
23homeostasis. Lymphangiogenesis or de novo lymphatic formation is closely associated with
24tissue inflammation in adults (i.e. wound healing, allograft rejection, tumor metastasis).
25Until recently, research on lymphangiogenesis focused mainly on growth factor/growth
26factor-receptor pathways governing this process. One of the lymphatic vessel features is
27the incomplete or absence of basement membrane. This close association of endothelial
28cells with the underlying interstitial matrix suggests that cell–matrix interactions play
29an important role in lymphangiogenesis and lymphatic functions. However, the explora-
30tion of interaction between extracellular matrix (ECM) components and lymphatic endo-
31thelial cells is in its infancy. Herein, we describe ECM–cell and cell–cell interactions on
32lymphatic system function and their modification occurring in pathologies including can-
33cer metastasis.
34! 2011 Published by Elsevier Ltd.
35
3637 Contents
38 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
39 2. Cell–cell interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
40 2.1. Classical organization of intercellular junctions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
41 2.2. Intercellular junctions in LEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
42 3. Cell–matrix interactions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
43 3.1. The extracellular matrix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
44 3.2. LEC anchorage to the ECM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
45 3.3. Role of integrins in LEC functions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
46 3.4. Impact of physical constraints on LEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
47 3.5. Matrix remodeling during lymphangiogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
48 4. LEC interactions with cancer cells and leukocytes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
49 5. Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
50 6. Uncited references . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
51 Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
52 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
53
54
0098-2997/$ - see front matter ! 2011 Published by Elsevier Ltd.
doi:10.1016/j.mam.2011.04.002
⇑ Corresponding author. Address: Laboratory of Tumor and Developmental Biology, GIGA-Cancer, University of Liège, Tour de Pathologie, CHU (B23) Sart
Tilman, Avenue de l’Hôpital 3, B-4000 Liège, Belgium. Tel.: +32 4 366 25 69; fax: +32 4 366 29 36.
E-mail address: agnes.noel@ulg.ac.be (A. Noël).
Molecular Aspects of Medicine xxx (2011) xxx–xxx
Contents lists available at ScienceDirect
Molecular Aspects of Medicine
journal homepage: www.elsevier .com/locate /mam
JMAM 429 No. of Pages 13, Model 3G
4 May 2011
Please cite this article in press as: Paupert, J., et al. Lymphangiogenesis in post-natal tissue remodeling: Lymphatic endothelial cell con-
nection with its environment. Molecular Aspects of Medicine (2011), doi:10.1016/j.mam.2011.04.002
55 1. Introduction
56 The adult lymphatic system is composed of peripheral capillaries, collecting vessels, lymph nodes, larger trunks and the
57 thoracic duct. Lymphatic vessels are present in the skin and in most internal organs except central nervous system, bone
58 marrow, retina and avascular tissues such as cartilage, hair, nails, cornea and epidermis (Tammela and Alitalo, 2010). Lym-
59 phatic capillaries (also referred to in the literature as initial lymphatics or absorbing lymphatics), the initial absorptive part
60 of the lymphatic vasculature, are blind-ended vessels formed by a single layer of lymphatic endothelial cells (LEC) devoid of
61 pericyte coverage and continuous basement membrane (BM) (Fig. 1). In contrast, collecting lymphatic vessels are coated by
62 perivascular smooth muscle cells to allow fluid propulsion and contain valves to prevent backflow (Lund and Swartz, 2010).
63 The main physiological function of the lymphatic vasculature is to maintain tissue fluid homeostasis through the uptake of
64 fluid and macromolecules that leak out of blood capillaries into interstitial tissues spaces, and return them back to the blood
65 circulation via the inferior vena cava in the form of lymph. In addition, the lymphatic system plays an important part in im-
66 mune defenses against infection through the transport of antigen presenting cells to the lymph nodes and of lymphocytes
67 exiting in lymph nodes. It also contributes to the intestinal fatty acid and fat absorption and transport (for review see,
68 von der Weid and Rainey, 2010; Wang and Oliver, 2010). The absence of lymphatic system is incompatible with life, and
69 lymphatic dysfunctions lead to chronic lymphedema and impaired immune responses (Karpanen and Alitalo, 2008).
70 Lymphangiogenesis, the formation of new lymphatic vessels from pre-existing one, is primarily an embryonic event
71 (Karpanen and Alitalo, 2008; Makinen et al., 2007). In adults, this process is closely associated with tissue inflammation
72 and occurs in wound healing, chronic inflammation, autoimmunity, allograft rejection and tumor metastasis (Achen et al.,
73 2005; Huggenberger et al., 2010; Mouta and Heroult, 2003; Regenfuss et al., 2008). During inflammatory conditions, lymph-
74 atics facilitate tissue edema resolution and immune response. Postnatal inflammatory lymphangiogenesis is extensively
75 studied in the cornea which is avascular under physiological conditions, but can undergo blood and lymphatic neovascular-
76 ization under certain inflammatory conditions such as corneal graft or infections (Ellenberg et al., 2010; Regenfuss et al.,
77 2008). Indeed, graft rejection is attributed in part to lymphangiogenesis. Of great interest is the recent demonstration that





































Fig. 1. Schematic overview of the structure and function of the lymphatic vasculature. Fluid containing proteins, lipids and other solutes is leaking out from
blood vessels (BV), percolates through the interstitial tissue and returns to the circulation by the venous capillary bed and lymph vessels (LV). Endothelial
cells of lymphatic capillaries have an oak shaped with overlapping scalloped edges (flaps). These flaps are only sealed on the sides by discontinuous button-
like junction (BJ) allowing fluid entry through these flaps without disturbing cell–cell cohesion. Lymph then moves to collecting vessels specialized in fluid
transport by perivascular smooth muscle cells coverage that allows fluid propulsion. The collecting lymphatics contain valves to prevent backflow. Immune
cells (lymphocytes (L), macrophages (M), dendritic cells (DC)) likely enter lymphatic capillaries through the intermingled flaps. In contrast to BV, interstitial
matrix constitutes the principal microenvironment of initial lymphatic since they are devoid of a continuous basement membrane (BM). Anchoring
filaments connect lymphatic capillaries to extracellular matrix and modulate vessel diameter by pulling adjacent endothelial cells apart. Lymphatic
endothelial cells (LEC), blood endothelial cells (BEC), fibronectin (FN), hyaluronan (HA).
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79 et al., 2008). In cancer, tumor spread to regional lymph nodes which is one of the most common route of tumor spread for
80 several human cancers such as breast, prostate, cervical and colon carcinomas as well as melanomas (for review see, Tam-
81 mela and Alitalo, 2010). The lymph node status is a major determinant for cancer staging and prognosis, guiding finally the
82 therapeutic decisions (Sleeman and Thiele, 2009). According to the current view of lymphatic dissemination, tumor cells
83 spread through the lymphatic system either by intravasating into pre-existing lymphatic vessels at the tumor periphery
84 or through neo-formed lymphatics induced by the secretion of growth factors within tumor (Sleeman and Thiele, 2009).
85 However, whether tumor cell detection in lymph node serves as evidence of tumor cell trafficking through lymph nodes prior
86 to more distant organs or reflects an inflammatory process and/or invasive properties of tumor cells remains to be elucidated
87 (Sleeman and Thiele, 2009). Recently, Hirakawa and colleagues have demonstrated that tumor cells can also induce lym-
88 phangiogenesis within lymph nodes themselves (Hirakawa, 2010). This modified lymph node microenvironment likely acts
89 as an intermediate niche promoting cancer cell survival and contributing to enhanced metastasis to distant lymph nodes and
90 organs.
91 A better understanding of the molecular signaling pathways that control lymphatic vessel formation and function is man-
92 datory to develop therapeutic drugs that inhibit lymphangiogenesis to prevent tumor spread or graft rejection. On the oppo-
93 site, identification of pathways that could restore lymphangiogenesis in disease setting of lymphedema will provide great
94 benefit to cure patients. Important advances in lymphangiogenesis field have been achieved thanks to the discovery of spe-
95 cific LEC markers (Alitalo et al., 2005) and the identification of some of its molecular mediators. LEC markers include lym-
96 phatic vessel hyaluronan receptor-1 (LYVE-1), the Prospero-related homeobox transcription factor 1(Prox-1), the forkhead
97 box transcription factor Foxc2, the chemokine CCL21, and VEGF receptor VEGFR-3 (Norrmen et al., 2011). They are all highly
98 expressed in all lymphatic vessels during embryonic development. Their expression is downregulated in mature collecting
99 vessels with the exception of Prox-1, Foxc-2 and VEGFR-3 still expressed on collecting vessel valves. Lymphatic capillaries
100 continue to express high levels of LYVE-1, Prox-1, and VEGFR-3 and the cell surface mucoprotein podoplanin (Norrmen
101 et al., 2011). Mechanisms mediating physiological and pathological lymphatic vessel growth involve multiple growth fac-
102 tor/growth factor-receptor pathways. The VEGF-C/D-VEGFR-3 signaling pathway is the most documented one (Adams and
103 Alitalo, 2007; Da et al., 2008; Sleeman and Thiele, 2009; Tammela and Alitalo, 2010). Consequently, this molecular pathway
104 is the main target of current therapeutic strategies that are being investigated to suppress lymphangiogenesis as described in
105 recent elegant reviews (Norrmen et al., 2011; Witte et al., 2011).
106 Although the development of lymphatic vascular network occurs within the interstitium of most tissues, the exploration
107 of the interactions occurring between extracellular matrix (ECM) components and LEC is in its infancy. The present review
108 will mainly focus on lymphatic capillaries that take part to fluid, macromolecule and cell uptake, and contribute to new lym-
109 phatic vessel formation. It will shed light on the role of ECM–cell and cell–cell interactions on lymphatic capillary function
110 and lymphangiogenesis in pathologies including cancer metastasis.
111 2. Cell–cell interactions
112 2.1. Classical organization of intercellular junctions
113 In the endothelium, cell–cell contacts control critical endothelial cell functions such as restrained migration, prolifera-
114 tion, apoptosis, and maintenance of differentiation through apical–basal polarity (Dejana et al., 2009). Junctional com-
115 plexes comprise three distinct categories: (1) gap junctions; (2) tight junctions (TJs), and (3) adhering junctions (Fig. 2).
116 Gap junctions are clusters of intercellular channels formed by the alignment of connexons composed of connexins. They
117 allow chemical and electrical communications between neighboring cells through the passage of ions and small molecules
118 across adjacent cell membranes (Goodenough and Paul, 2009). In contrast, TJs prevent the passage of molecules and ions
119 through the intercellular space and also delimitate cellular polarity by restricting the movement of integral membrane
120 proteins and lipids between the apical and the basolateral plasma membrane (Furuse, 2010). TJs are composed of integral
121 membrane proteins (claudins, occludins, tricellulin), cytoplasmic plaque proteins (zona occludens (ZO) proteins, cingu-
122 lin,. . .) and cytoskeletal proteins (actin). In addition, a number of immunoglobulin superfamily membrane proteins includ-
123 ing junctional adhesion molecule (JAM), coxsackie adenovirus receptor (CAR) and endothelial cell-selective adhesion
124 molecule (ESAM) are localized at TJs and play a role in vessel permeability and/or leucocyte trafficking through the endo-
125 thelium (Guo et al., 2009; Orlova and Chavakis, 2007; Wegmann et al., 2006). The adhering junctions are known to main-
126 tain the physical association between cells by linking plasma membranes and cytoskeletal components. They are divided
127 in two categories: (i) adherens junctions (AJs) tethering microfilaments and (ii) desmosomes linked to intermediate fila-
128 ments (Meng and Takeichi, 2009). The adhering junctions are either calcium-dependent (cadherins) or calcium-indepen-
129 dent (nectins) proteins that have single-pass transmembrane and bind to the members of armadillo family, such as
130 catenins, plakoglobin and plakophilins. The cytoplasmic tails of cadherins and their associated armadillo proteins are
131 embedded within a meshwork of cytoskeletal adaptor proteins and associated with cytoskeletal fibers. Desmogleins and
132 desmocollins are both desmosome cadherins that have a similar ectodomain structure as classical cadherins (E, N, P cad-
133 herins), but the structural features of their cytoplasmic domains are divergent. They bind to the members of the armadillo
134 (plakoglobin, plakophilins) and plakin (desmoplakin) family and contribute to keratin filament organization (Berx and van
135 Roy, 2009; Delva et al., 2009).
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136 2.2. Intercellular junctions in LEC
137 Gap junctions were described only in collecting vessels where these junctions play a role in the propagation and coordi-
138 nation of contractions in lymphatics in the mesentery of the rat small intestine (Zawieja et al., 1993). Recently, Ferrell et al.





















































Fig. 2. The main molecular players of cell junctional complexes and cell–matrix interactions. Molecular players found in LEC are written in red. Junctional
adhesion molecule (JAM), coxsackie adenovirus receptor (CAR), endothelial cell-selective adhesion molecule (ESAM), zona occludens (ZO), cell adhesion
molecules (CAM), multi-PDZ domain protein (MUPP1), PALS1-associated tight junction protein (PATJ), epithelial protein lost in neoplasm (EPLIN). (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Table 1
Mouse knock-out models and human mutations of cell–cell and cell–matrix molecules associated with a lymphatic phenotypeQ3 .
Lymphatic phenotype References
GJC2 (encoding connexin 47) missense mutations in
human
Lymphedema Ferrell et al. (2010)
Col18a1!/! mice Enhanced corneal lymphangiogenesis after keractectomy wound Kojima et al. (2008)
Emilin 1!/! mice Reduction of anchoring filaments Danussi et al.
(2008)
Hyperplastic and enlarged lymphatic vessels
Develop larger lymphangioma
Lymph leakage
Integrin a9!/! mice Severe bilateral chylotorax Huang et al. (2000)
Abnormal lymphatic valves Bazigou et al.
(2009)
Edema and inflammatory cell accumulation in the chest wall
Missense mutation in human integrin a9 gene
(c.1210G > A, p.G404S)
Severe bilateral chylothorax Ma et al. (2008)
Integrin a1b1!/! mice Decreased of lymphangiogenesis after cornea transplantation Chen et al. (2005)
Tie2Cre + a4loxp/loxp mice Lymphangiogenesis reduced in a in vivo matrigel plug assay Garmy-Susini et al.
(2010)
Integrin a4Y991A knock-in mutation (mice) Lymphangiogenesis reduced in an in vivo matrigel plug assay and in
the lymphatic ring assay
Garmy-Susini et al.
(2010)
Reduction of metastasis to lymph node
Reduction of tumor-induced lymphangiogenesis
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140 TJs and AJs are not as frequently seen in lymphatics as in blood vessels (Leak and Burke, 1968; Pepper and Skobe, 2003).
141 Adherens and tight junction proteins in LEC have been detected by immunohistochemistry and gene array profiling, and in-
142 clude VE-cadherin, occludin, claudin-5, ZO-1, ESAM and JAM-A, JAM-B, -C as well as CAR (Aurrand-Lions et al., 2001; Baluk
143 et al., 2007; Hirakawa et al., 2003; Ueki et al., 2008; Vigl et al., 2009). CAR is expressed specifically by human LEC, but not
144 murine LEC (Raschperger et al., 2006; Vigl et al., 2009). The knock-down of CAR in human LEC by specific siRNAs leads to a
145 reduction of LEC–LEC adhesion, migration and tube formation into collagen matrix. Interestingly, CAR re-expression in LEC
146 restores these LEC properties in vitro. The expression of LEC adhesion and junctional proteins seems to be modulated during
147 cancer progression (Clasper et al., 2008). Gene array analyzes of LEC isolated from tumors in comparison to LEC isolated from
148 normal tissue show downregulation of JAM-B, N-cadherin, cadherin-11, whereas JAM-A, ESAM and CAR are upregulated in
149 tumor-associated LEC. The upregulation of ESAM in tumor-associated LEC is confirmed by immunostaining (Clasper et al.,
150 2008).
151 An adhering junction (‘‘complexus adherens’’) specific to LEC has been evidenced in various human, bovine and rodent
152 tissues (Schmelz et al., 1994). These junctions are usually larger than desmosomes and characterized by a dense plaque con-
153 taining plakoglobin and desmoplakin, but not desmoglein and desmocollin. These «Complexus adhaerens» are also positive
154 for a-catenin, VE-cadherin, ZO-1 and claudin 5 (Hammerling et al., 2006). Comparative gene array analyzes of cultured pri-
155 mary blood endothelial cells (BEC) and primary LEC revealed that desmoplakin is upregulated in LEC (4.6-fold) (Hirakawa
156 et al., 2003). Immunohistochemical study demonstrates that desmoplakin is detected in small lymphatic vessels, but not
157 in the thoracic duct or blood vessels (Schmelz et al., 1994). This observation has been also confirmed on human tongue tissue
158 (Ebata et al., 2001).
159 The elegant ultrastructural study of Baluk et al. (2007) has revisited the initial view of lymphatics displaying poorly devel-
160 oped or no intercellular junctions (Leak and Burke, 1968). This study reports that junctions between LEC in lymphatic cap-
161 illaries are unique at likely sites of fluid entry. Endothelial cells of capillaries display a typical oak leaf shape that differs from
162 the classical spindle-shaped endothelial cells of collecting lymphatics and blood vessels (Fig. 1). These oak leaf shaped cells
163 extend overlapping scalloped edges (flaps) resembling valve-like structures. These flaps lack junctions at the tip are sealed
164 on the sides by discontinuous button-like junctions containing AJ and TJ proteins (Baluk et al., 2007) (Fig. 1). Thus, the
165 authors hypothesized that these junctions would permit fluid entry through the opening of these free flaps and without dis-
166 rupting the overall junctional organization. The more distal collecting vessels have continuous zipper-like junctions resem-
167 bling those of blood vessel endothelium. The main differences between buttons and zippers rely on their organization rather
168 than their composition. It is worth noting that the presence of button-like structures does not translate the dynamic feature
169 of the immature region of lymphatic sprouts, since zippers like junctions, but not buttons are seen in growing tips of lymph-
170 atics neoformed in a sustained inflammation model of lymphangiogenesis (Baluk et al., 2007). In addition, discrepancies can
171 be found between data generated in vitro and in vivo regarding junction composition and function since LEC monolayer does
172 not show button junction but rather zipper (Kriehuber et al., 2001).
173 3. Cell–matrix interactions
174 3.1. The extracellular matrix
175 One of the feature of lymphatic capillaries is the incomplete or absence of BM (Leak and Burke, 1968). This characteristic
176 might be related to low levels of BM component production by LEC (Hirakawa et al., 2003; Podgrabinska et al., 2002) or to the
177 lack of pericytes which are an abundant source of BM constituents (Petrova et al., 2004; Stratman et al., 2009). In line with
178 this latter hypothesis is the observation of lymphatic capillaries in Foxc2!/! mice that are invested by pericytes and sur-
179 rounded by a deposition of BM components such as collagen IV. Thus, in contrast to BEC, the interstitial matrix and fluid
180 constitute the principal microenvironment of LEC, both in physiological and pathological conditions. Major extracellular ma-
181 trix (ECM) components include collagens, proteoglycans, fibronectin, laminins, elastin and vitronectin (Miner and Yurchen-
182 co, 2004). For the description of ECM components, readers are referred to recent reviews addressing their structure and their
183 role in cell function regulation (Durbeej, 2010; Gordon and Hahn, 2010; Kielty, 2006; Schaefer and Schaefer, 2010; Singh
184 et al., 2010; Wiig et al., 2010). Here, we focus on the description of interstitial matrix components known to affect the func-
185 tion of lymphatic capillaries and lymphangiogenesis.
186 The primary scaffold of interstitial matrix surrounding lymphatic capillaries is made of fibrillar collagens that entrap pro-
187 teoglycans and glycoproteins. Interstitial collagens and fibrin both serve as provisional matrices during wound healing
188 (Helm et al., 2007). The fact that LEC are in close contact with the interstitial matrix can also explain the higher LEC survival
189 and tubulogenesis observed on type I collagen without exogenously added growth factors, a condition in which BEC poorly
190 survive (Podgrabinska et al., 2002). We recently set up a 3D model of lymphatic ring cultures (Bruyere et al., 2008) in which
191 LEC sprout and organize into tube-like structures in a type I collagen gel, but not in a basement reconstituted matrix (matri-
192 gel) (Noel personal data). In the presence of growth factors and fluid flow, BEC organize better in a matrix composed of equal
193 amount of collagen and fibrin, whereas LEC organize better in a matrix composed of fibrin only (Helm et al., 2007). However,
194 in other studies, collagen matrix promotes LEC tube formation without flow and growth factor added (Leak and Jones, 1994;
195 Podgrabinska et al., 2002). Differences in the experimental design and conditions used to perform the tubulogenesis assay
196 (such as cell suspension in the collagen gel or seeding between two collagen layers and the type of collagen used) can explain
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197 discrepancies between results. In vivo, in secondary lymphedema induced by skin excision in the mouse tail, type I collagen
198 accelerates lymphatic regeneration and wound repair further supporting its role in the control of lymphatic cell function
199 (Clavin et al., 2008). As previously described for angiogenesis (Hamano et al., 2003), some collagen fragments also exert
200 an inhibitory effect on lymphangiogenesis. For instances, endostatin and neostatin 7, fragments of collagen type XVIII inhibit
201 lymphangiogenesis (Brideau et al., 2007; Kojima et al., 2008). Accordingly, collagen XVIII-deficient mice exhibit increased
202 corneal lymphangiogenesis after keratectomy wound (Kojima et al., 2008) (Table 1).
203 Hyaluronan (HA) is a major ECM constituent which regulates cell proliferation and migration, as well as controls matrix
204 stability and water retention (Jackson, 2009). It is a polymer of disaccharides, themselves composed of d-glucuronic acid and
205 D-N-acetylglucosamine, ranging in size from 104 to 107 Da. HA has been assigned various physiological functions due to its
206 viscoelastic properties, its hygroscopic capacities. Polymers are either anchored firmly in the plasma membrane or bound via
207 receptors (Nusgens, 2010). One third of HA is replaced daily in tissues in which a part of it is removed by the lymphatic ves-
208 sels and/or degraded by lymphatic cells in the lymph nodes. In mammary tumors, HA increases intratumoral lymphangio-
209 genesis and lymphatic vessels are mostly found in association with HA-rich stroma (Koyama et al., 2008). Accordingly,
210 similar results are reported in idiopathic pulmonary fibrosis where HA is found around lymphatic vessels and short frag-
211 ments of HA induce lymphangiogenesis (El-Chemaly et al., 2009). Lymphatic hyaluronan receptor, Lyve-1, is one of the lym-
212 phatic marker commonly used. However, Lyve 1!/! mice display normal phenotype, have a functional lymphatic network
213 and a normal hyaluronan metabolism which is likely due to compensatory mechanisms by other HA-receptors (Gale et al.,
214 2007). However, Lyve-1 null mice show larger lymphatic vessels with distended lumen in liver and intestine, but not in other
215 tissues tested (lung, ovary, uterus, vagina, cervix, salivary gland, skin, kidney, brain and foot pad) (Huang et al., 2006).
216 Finally, lymphatic vessels are surrounded by patches of fibronectin (Oh et al., 1997) that is known to enhance VEGF-C-
217 mediated LEC proliferation in vitro (Zhang et al., 2005). Interestingly, the spliced variant fibronectin EDA (fibronectin-EIIIA,
218 also called EDA and containing EDA domain) detected in the tumor stroma but not in normal tissue, stimulates LEC tubulo-
219 genesis (Ou et al., 2010). Netrin-4, a laminin-related secreted protein, is also a pro-lymphangiogenic factor. Netrin-4 impli-
220 cated in neuron guidance during development is also expressed by LEC and induces LEC proliferation, migration and survival.
221 Its overexpression in tumors increases the number of lymphatics, reduces lymphatic vessel permeability and enhances
222 metastasis (Larrieu-Lahargue et al., 2010).
223 3.2. LEC anchorage to the ECM
224 An additional feature of lymphatic capillaries is their close connection to surrounding tissue by a fibrillar elastic apparatus
225 which is absent in blood vessels (Gerli et al., 1990). All fibers of this apparatus are composed of microfibrils that ensure the
226 link between lymphatic vessels and the surrounding tissue. This fibrillar elastic apparatus is composed of three successive
227 types of interconnected fibers including (from the capillary wall to the tissue): (1) oxytalan (usually called anchoring fila-
228 ment) composed of microfibril bundles associated to the abluminal surface of lymphatic capillaries, (2) elaunin consisting
229 of microfibrils embedded in a small amount of elastin and finally, (3) elastic fibers contain elastin surrounded by microfibrils
230 (Gerli et al., 1990). These filaments are extremely important for draining the excess of extracellular fluid occurring during
231 tissue injury, inflammation or tumor growth. Increased interstitial pressure stretches the connective tissue fibers and
232 anchoring filaments, pull adjacent endothelial cells apart and increase the diameter of lymphatic vessels that are usually col-
233 lapsed under normal circumstances. This increase of lymphatic lumen is essential for fluid and particles passage into the
234 lymphatics (Ji, 2006). The importance of anchoring filament in lymphatic function has been recently demonstrated through
235 the generation of Emilin1!/! mice (Danussi et al., 2008). EMILIN1 (elastin microfibril interface-located protein 1) is a con-
236 nective tissue glycoprotein associated with elastic fibers in the extracellular matrix of blood vessels as well as in connective
237 tissue of other organs (Bressan et al., 1993; Colombatti et al., 2000). EMILIN1 is expressed at the abluminal surface of LEC as
238 well as in the fibers radiate from LEC. The number of anchoring filaments is significantly reduced in Emilin1!/! mice and
239 these mice show leaky lymphatic vessels (Table 1).
240 3.3. Role of integrins in LEC functions
241 Most of the effects of ECM components on lymphangiogenesis are mediated via integrins. Integrins are a large family of
242 heterodimeric transmembrane glycoproteins that mediate cell–ECM or cell–cell interactions. Integrins contain 18 large (a)
243 and eight small (b) subunits generating 24 heterodimers (Avraamides et al., 2008). Integrins serve as transmembrane linkers
244 between their extracellular ligands and the cytoskeleton and associated intracytoplasmic partners. Through these multiple
245 interactions, they control cell adhesion, migration and differentiation in physiological and pathological conditions. Effect of
246 fibronectin and EDA fibronectin domain mentioned above are mediated by a5b1 and a9b1, respectively (Ou et al., 2010;
247 Zhang et al., 2005). The a9 integrin mediates LEC chemotaxis and migration of LEC toward VEGF-C (Mishima et al., 2007).
248 It has been shown that a9 integrin binds directly VEGF-C and D (Vlahakis et al., 2005). Integrin a9b1 is currently viewed
249 as a major integrin associated with lymphangiogenesis since this integrin is required for the development of the lymphatic
250 system (Huang et al., 2000). The known ligands of a9b1 are tenascin, fibronectin, thrombospondin, VCAM-1, collagen and
251 laminin. Until recently, none of these ligands were known to affect lymphangiogenesis in vivo. Mice lacking the integrin
252 a9b1 died shortly and develop chylotorax, edema and inflammatory cell accumulation around the thoracic duct. Chylotorax
253 has also been described in human fetuses carrying a mutation in the a9 integrin subunit gene (Ma et al., 2008) (Table 1).
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254 Mice deficient in integrin a9 show abnormal lymphatic valves due to a defective fibronectin matrix organization. Consis-
255 tently, the interaction between integrin a9 present at LEC surface and fibronectin-EIIIA (EDA) is known to regulate fibronec-
256 tin matrix assembly (Bazigou et al., 2009). However, EDA-deficient mice do not show chylothorax which suggest that the
257 phenotype observed in integrin a9-deficient mice is not only due to impaired interaction with EDA, or a compensatory
258 mechanisms take place in EDA-deficient mice. Tenascin-C is also described in the vicinity of the lymphatic valves and known
259 to interact with a9 integrin, the lack of this interaction in integrin a9-deficient mice might explain the lymphatic altered
260 function phenotype of these mice. Further studies are required to address this issue.
261 Two other fibronectin binding integrins, a4b1 and a5b1 promote lymphangiogenesis (Dietrich et al., 2007; Garmy-Susini
262 et al., 2010; Okazaki et al., 2009). Recently, it has been shown that fibronectin and integrin a4b1 are upregulated in tumor
263 lymphatic endothelium, moreover, a4b1 inhibition significantly suppresses tumor lymphangiogenesis and lymph node
264 metastasis (Garmy-Susini et al., 2010). Important role of integrin a5 has been described in inflammatory lymphangiogenesis,
265 in both corneal and in airway inflammation (Dietrich et al., 2007; Okazaki et al., 2009). An in vitro study shows that integrin
266 a5b1 associates with VEGFR-3 and plays a role in VEGFR-3 mediated LEC proliferation (Zhang et al., 2005). Finally, a1b1 and
267 a2b1, both collagen and laminin receptor integrins participate in VEGF-A mediated lymphangiogenesis in wound healing
268 (Hong et al., 2004). Both integrins are upregulated upon VEGF-A treatment.
269 3.4. Impact of physical constraints on LEC
270 As mentioned above, lymphatic system maintains tissue fluid balance and clear proteins that are filtered across lymph-
271 atics. In normal conditions, there is a net fluid flow towards lymphatics. The interstitial flow emerged recently as an impor-
272 tant morphogenic factor of LEC (Boardman and Swartz, 2003; Goldman et al., 2007; Ng et al., 2004). Under flow condition
273 in vitro, VE-cadherin and PECAM containing junctions are modified and both protein expressions are decreased. In vivo,
274 an overhydration, induced by repetitive saline buffer injection, decreases VE-cadherin and PECAM expression without affect-
275 ing ZO-1 or occludin production (Miteva et al., 2010).
276 In most solid tumors, interstitial fluid pressure is increased due to blood vessel leakiness, low lymphatic drainage, inter-
277 stitial fibrosis and ECM contraction by fibroblasts infiltrating the tumor stroma (Heldin et al., 2004). Fibrosis is characterized
278 by an excessive ECM deposition that modifies the elasticity of the tissue. Clinical studies have established a link between
279 fibrosis and the development of lymphedema especially after hypertension, repeated infections or radiotherapy when com-
280 bined with axillary lymph node dissection (Goffman et al., 2004; Li et al., 2009; Stramer et al., 2007). During wound repair,
281 the decrease of fibrosis is associated with an increase of lymphatic regeneration and lymph transport (Avraham et al., 2009).
282 Moreover in fibrotic wounds, lymphatic capillaries become thicker and fibrotic i.e. lymphatic vessels express a-smooth mus-
283 cle actin that can interfere with the dilatation of vessels to resolve the lymphedema. Because of high intratumoral pressure,
284 lymphatic vessels inside the tumors may be occluded and non-functional, whereas at the tumor margins the pressure is
285 found to decrease dramatically and lymph vessels at the periphery of tumors are reported to be functional. The functionality
286 of intratumoral lymphatic vessels is still a topic of debate (Tammela and Alitalo, 2010). The interstitial flow also affects lym-
287 phangiogenesis. The excess of fluid leads to the formation of interstitial fluid channels that are formed before LEC organiza-
288 tion, and LEC migrate along those channels to organize into lymphatic vessels (Boardman and Swartz, 2003). All together,
289 these observations show that physical constrains control lymphangiogenesis and LEC functions at different levels.
290 3.5. Matrix remodeling during lymphangiogenesis
291 In normal tissue homeostasis, ECM composition is maintained through a fine balance between the synthesis and degra-
292 dation of its components. During pathological processes, this balance is disturbed by the overexpression of proteases includ-
293 ing at least, serine proteases (plasmin/plasminogen system) and matrix metalloproteases (MMPs). An extensive ECM
294 degradation induces a collapse of lymphatic capillaries and renders them non responsive to the increase of interstitial flow
295 (Negrini et al., 2008; Pelosi et al., 2007). During lymphangiogenesis, the sprouting of LEC from preexisting vessels and their
296 migration through ECM requires cells to negotiate the interstitial collagen and likely fibrin as provisional matrices for cell
297 migration. The primary fibrinolytic enzyme is plasmin generated through the cleavage of the zymogen plasminogen by plas-
298 minogen activators (tissue-type plasminogen activator or urokinase-type plasminogen activator) both controlled by their
299 physiological inhibitor (plasminogen activator inhibitor-1 or PAI-1) (Kwaan and McMahon, 2009). Since LEC express uPA,
300 it is expected that plasmin affects lymphangiogenesis. In vitro, plasmin activates the pro-lymphangiogenic factors, VEGF-C
301 and VEGF-D (McColl et al., 2003). Surprisingly, despite its key role in angiogenesis (Bajou et al., 1998), PAI-1 does neither
302 affect tumoral lymphangiogenesis, nor development of lymphangioma or burn-induced corneal lymphangiogenesis (Bruyere
303 et al., 2010; Masset et al., 2011).
304 MMPs encoded by 24 human and 23 mouse genes, include secreted and membrane-associated members. They can col-
305 lectively degrade all ECM components in addition to contributing to the processing of a plethora of cell function regulators
306 (growth factors, cell surface proteins, chemokines/cytokines,. . .) (Fanjul-Fernandez et al., 2010; Noel et al., 2008; Page-
307 McCaw et al., 2007). Although MMP contribution in angiogenesis is well documented, the exploration of MMP functions
308 in lymphangiogenesis is still in its infancy. Interestingly, increased of MMP-2 and MMP-9 production is observed in various
309 forms of lung edema, alterations associated with this disease could be in part related to proteoglycan degradation by these
310 two enzymes (Negrini et al., 2008). MMP2 and MMP9 are produced by LEC isolated from lymphangiomas (Nakamura et al.,
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311 2004) and by lymphatic capillaries sprouting from thoracic duct explants (Bruyere et al., 2008). A broad-spectrum MMP
312 inhibitor impairs LEC tubulogenesis in vitro and inhibits lymph node metastasis in vivo (Nakamura et al., 2004). Recently,
313 Matsuo et al. hypothetize that the inhibitory effect of curcumin on tube formation in vitro is partially mediated by MMP-
314 2 blockade (Matsuo et al., 2007). A more direct clue of MMP2 contribution in lymphangiogenesis is provided by the impaired
315 lymphangiogenesis observed in the lymphatic ring assay performed with lymphatic duct explant fromMMP-2 deficient mice
316 (Bruyere et al., 2008). In this model, MMP-9-deficiency does not affect lymphangiogenesis, this emphasizes the specific con-
317 tribution of MMP2 in this process. As seen in angiogenesis, the cleavage of ECM components by MMPs is expected to gen-
318 erate fragments endowed with lymphangio-inhibitory functions. For instance, as mentioned above, neostatin-7, a type XVIII
319 collagen fragment generated by MMP-7 inhibits corneal lymphangiogenesis probably by its association to VEGFR-3 (Kojima
320 et al., 2008).
321 4. LEC interactions with cancer cells and leukocytes
322 The transmigration of cells (cancer cells or leukocytes) through an endothelium is a multi-step process that involves cell
323 attraction by cell adhesion molecules and cell migration between endothelial cells. LEC in capillaries produce a panel of che-
324 mokines which attract leukocytes such as CCL-21, CXCL-12, MCP-1 and Rantes (Mouta and Heroult, 2003). For instance, CCL-
325 21 production by LEC has been described to attract both cancer cells and leukocytes. It is suggested that tumor cells use the
326 same mechanisms as immune cells to enter the lymphatic capillaries (Shields et al., 2007). Moreover, highly invasive cancer
327 cells are known to produce high levels of CCR-7 ligand, CCR-7, CCl-21 and CCL-19 receptors compared to poorly metastatic
328 cancer cell lines. In a 3D in vitro cell migration model, tumor cells migrate in a CCR-7 dependent manner towards LEC and
329 fluid flow enhances tumor cell migration (Shields et al., 2007). A complex molecular crosstalk between tumor cells and LEC
330 appears to be established during cancer invasion (Issa et al., 2009). Tumor-derived VEGFC increases CCL-21 secretion by LEC
331 which in turn drives CCR-7-dependent chemoinvasion of tumor cells toward lymphatics (Issa et al., 2009). In addition to this
332 paracrine effect, tumor cell attraction appears to be amplified by a so-called autologous chemotaxis (Shields et al., 2007).
333 According to this concept, CCR7-positive tumor cells which autocrinely produce CCR-7 ligand are surrounded by high con-
334 centration of this ligand and thus migrate and are guided toward the direction of the interstitial fluid flow.
335 LEC express various cell adhesion molecules (CAM) such as PECAM-1, VCAM-1, ICAM-1, ICAM-2 and E-selectin (Baluk
336 et al., 2007; Johnson et al., 2006; Raschperger et al., 2006; Sawa et al., 1999). Most of them are expressed at low levels on
337 normal lymphatic vessels and are upregulated upon inflammatory stimuli or under increased interstitial flow (Johnson
338 et al., 2006; Miteva et al., 2010; Sawa et al., 2008). Dendritic cells (DC) transmigration requires the adhesion via ICAM-1
339 and VCAM-1 that is a prerequisite step for transmigration across lymphatic vessels (Johnson et al., 2006). The interaction
340 of DC with lymphatic vessels via ICAM-1 also modulates DC differentiation and functions (Podgrabinska et al., 2009). PE-
341 CAM-1 involvement in leukocyte migration through lymphatics seems to be dependent on the mice genetic background.
342 In C57BL/6 background, PECAM-1 is not involved in leucocyte migration through lymphatic endothelium (Baluk et al.,
343 2007). Furthermore, PECAM-deficient FVB/nmice have reduced leukocyte emigration in acute models of inflammation, while
344 PECAM-deficient C57BL/6 mice display normal responses (Schenkel et al., 2006, 2004). The PECAM-1-independent leukocyte
345 transmigration is unique to C57BL/6 mice since a reduced leukocyte emigration is also observed in different strains of mice
346 or rat using anti-PECAM Abs (Schenkel et al., 2004). A quantitative trait locus mapping between PECAM-deficient FVB/n and
347 C57BL/6 mice has identified a single locus, at 35.8 Mb on murine chromosome 2, associated with PECAM-independent leu-
348 kocyte transmigration in model of peritonitis. However, the specific gene involved in this process is still unknown (Seidman
349 et al., 2009). In cancer, ICAM-1 produced by LEC has been described to also mediate breast adenocarcinoma cell adhesion to
350 human LEC (Kawai et al., 2008). Moreover, conditioned media from highly metastatic MDA-MB-231 cells, but not from
351 poorly metastatic MCF-7 cells induce an upregulation of ICAM-1 by LEC, which in turn stimulates cancer cell adhesion to
352 LEC. This study emphasizes the importance of ICAM-1 in the establishment of a cross talk between tumor cells and LEC. Addi-
353 tional membrane proteins produced by LEC are contributing to endothelial transmigration. Common lymphatic and vascular
354 endothelial receptor CLEVER-1/Stabilin-1 and mannose receptor (MR), both expressed by LEC are involved in lymphocyte
355 trafficking (Salmi et al., 2004). MR allows binding of L-selectin positive lymphocytes to LEC (Irjala et al., 2001). In vivo, CLE-
356 VER-1 blockade or the MR absence on LEC impairs B and T cell trafficking from the periphery into the lymph node (Karikoski
357 et al., 2009; Marttila-Ichihara et al., 2008). Interestingly, both CLEVER-1 and MR mediate the adhesion of lymphomas and
358 head and neck squamous cell carcinoma (HNSCC) to lymphatic endothelium in vitro (Irjala et al., 2003). Immunohistochem-
359 ical study of MR performed on 17 tumor tissues biopsies of HNSCC and 72 breast carcinoma, show that intratumoral lymph
360 vessel MR expression is associated with the presence of axillary lymph node metastases at the time of diagnosis (Irjala et al.,
361 2003). Experimental studies using MR deficient mice support the importance of the lymphatic MR in metastatic dissemina-
362 tion. Indeed, B16 melanoma cells fail to metastasize to local lymph nodes of MR deficient (Marttila-Ichihara et al., 2008). An
363 additional LEC expressed membrane protein involved in cell adhesion is Thy1, a thymus cell antigen. It is expressed at high
364 levels on mouse LEC but not on BEC (Jurisic et al., 2010). As assessed by immunofluorescent staining, lymphatic vessels of
365 normal tissues express low Thy1 levels, while those of human prostate cancer tissue express high Thy-1 levels. Thy-1 block-
366 ing antibody decreases tumor cell adhesion on mouse LEC monolayer and leukocyte adhesion on human LEC monolayer
367 stimulated with phorbol myristate acetate. Cell adhesion to Thy-1 seems to be integrin-dependent. Indeed, Thy-1 protein
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368 sequence contains an integrin binding site promoting the interaction with aMb2 on leucocytes and aVb3 on melanoma cells
369 (Saalbach et al., 2005; Wetzel et al., 2004).
370 Current knowledge of the mechanisms underlying leukocyte and cancer cell entry into lymphatics is extremely sparse
371 and whether cell trafficking occurs in a passive or an active way is still being debated. Under basal condition, immune cells
372 intravasate into lymphatics in a passive manner (Lund and Swartz, 2010). However, more and more studies show that under
373 inflammation and/or in the tumor microenvironment, cell junction proteins, cell adhesion molecules and other membrane
374 proteins are actively involved in lymphatic endothelial transmigration. Button-rich junctions are currently viewed as gate
375 keepers for leucocyte entry. Few or no MHC-II positive cells (mainly DC and macrophages) has been detected to be associated
376 with LEC in vivo on resting lymphatic vessels (Baluk et al., 2007). After bacterial lypopolysaccharide exposure, most leuko-
377 cytes are associated with the button-rich junctions. However, whether leukocytes enter through openings between button-
378 rich regions of lymphatic capillaries is not yet solved. Dendritic cell association at the button-rich junctions has also been
379 described in response to an increase of interstitial flow (Miteva et al., 2010). Another argument on the role of LEC junctions
380 in cellular transmigration is the increased DC transmigration through lymphatic endothelium observed in JAM-A deficient
381 mice (Cera et al., 2004).
382 5. Concluding remarks
383 Recent progresses in the field of lymphangiogenesis offers new therapeutic options and led to the development of anti-
384 lymphangiogenesis drugs to inhibit tumor lymphangiogenesis, metastatic spread or graft rejection. Given that the VEGF-C/
385 VEGF-D/VEGFR-3 axis is the best validated signaling pathway for promoting lymphangiogenesis, different strategies have
386 been used to block these growth factors and their receptors or co-receptor (such as neuropilin-2) (Norrmen et al., 2011).
387 Neutralizing antibodies (anti-VEGFR-3, VEGF-C/D or neuropilin-2), as well as soluble VEGFR-3 fusion proteins (VEGF-C/D
388 trap) and siRNA targeting VEGF-C mRNA have proven efficacy to counteract tumor-induced lymphangiogenesis (Chen
389 et al., 2005; He et al., 2008, 2002; Lin et al., 2005; Rinderknecht et al., 2010; Roberts et al., 2006; Tvorogov et al., 2010). A
390 novel soluble form of VEGFR-2 issued from an alternative splicing emerged recently as a novel putative inhibitor of lymphan-
391 giogenesis (Albuquerque et al., 2009). Interestingly, blocking peptides against VEGFR-3 specifically inhibit corneal lymphan-
392 giogenesis in animal models without affecting hemangiogenesis (Bock et al., 2008). Another signaling system with specificity
393 to endothelial cells consists of the tyrosine kinase Tie receptor (Tie 1 and Tie2) and angiopoietin ligands (Ang1 and Ang2). It
394 offers an additional option to block lymphangiogensis (Tammela et al., 2005). Small-molecule inhibitors of tyrosine kinase
395 activity often lack specificity and block different pathways (e.g. VEGFRs, FGFRs and PDGFRs). Inhibitors of both VEGFR-2 and
396 VEGFR-3 like Sorafenib or Sunitinib (SU-11248) lead to the blockade of angiogenesis and lymphangiogenesis associated to
397 tumor and injured cornea (Bauerschlag et al., 2010; Bono et al., 2010; Gridelli et al., 2007; Perez-Santonja et al., 2010; Rosko-
398 ski, 2007; Young et al., 2010). It is anticipated that blocking different pathways involved in pathological lymphangiogenesis
399 will be required for optimal effect and to avoid the development of resistance against treatment. A complementary strategy
400 could interfere with chemokines such as CCL21 or CXCL12 (SDF-1) involved in tumor cell dissemination (Kim et al., 2010;
401 Lanati et al., 2010). Thanks to the evidence of the specific interactions of lymphatic endothelial cells with their interstitial
402 environment, therapeutic strategies could also include the blockage of cell matrix interaction by interfering with integrins
403 (Dietrich et al., 2007; Garmy-Susini et al., 2010) or the inhibition matrix remodeling enzymes (Bruyere et al., 2008). It is
404 worth mentioning that most of the anti-lymphangiogenic approaches that have emerged until now, have been derived from
405 animal studies. These results must be taken with care since the intensity of lymphangiogenic response and its inhibition var-
406 ied with the mouse genetic background (Regenfuss et al., 2010). Moreover, emerging concept such as the fact that tumor
407 cells actively enter into lymphatic vasculature by using cell adhesion molecule and receptors need to be consolidated in or-
408 der to design new drugs. Further characterization of potential candidates to be targeted is required. In this context, a better
409 understanding of LEC interactions with its surrounding cellular and molecular environment may enhance our mechanistic
410 knowledge and ultimately lead to the design of new therapeutic drug to regulate lymphangiogenesis.
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